Loss of life expectancy that would result if colorectal cancer missed in 2011 had been diagnosed in 2011 (unit: years). by Hiroaki Saito (24514)

Subjects:

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Subjects:

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Subjects:

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

Subjects:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Loss of life expectancy by age group and stage of colorectal cancer and change if detected after one year. by Hiroaki Saito (24514)

Subjects:

Estimated distribution of colorectal cancer stage among patients assumed to have missed diagnosis in 2011 (unit: persons). by Hiroaki Saito (24514)

Subjects:

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Additional loss of life expectancy and cost per life-year saved resulting from changes in colorectal cancer stage due to a 1-year diagnostic delay. by Hiroaki Saito (24514)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Subjects:

Table 2_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Table 1_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Table 3_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Alterations of Ceramides, Acylcarnitines, GlyceroLPLs, and Amines in NSCLC Tissues by Jie Zhang (64655)

Subjects:

Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

Subjects: